Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. 06628
stocks logo

06628

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast 06628 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06628 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 06628 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06628 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 2.640
sliders
Low
Averages
High
Current: 2.640
sliders
Low
Averages
High
no data image
No Data

Valuation Metrics

The current forward P/E ratio for TRANSCENTA-B (06628.HK) is -3.44, compared to its 5-year average forward P/E of -2.37. For a more detailed relative valuation and DCF analysis to assess TRANSCENTA-B 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.37
Current PE
-3.44
Overvalued PE
-1.02
Undervalued PE
-3.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.90
Current EV/EBITDA
-8.32
Overvalued EV/EBITDA
-0.04
Undervalued EV/EBITDA
-5.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.97
Current PS
82.31
Overvalued PS
57.55
Undervalued PS
-9.62
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

06628 News & Events

Events Timeline

Sign Up For More Events
no data image
No Data
Sign Up For More Events

News

[object Object]
Preview
9.0
09:22 AMGlobenewswire
PinnedTranscenta Updates Efficacy Analysis of Osemitamab, Achieving 16.6 Months PFS
  • Clinical Efficacy Update: At the ESMO Asia Congress, Transcenta presented updated efficacy analysis of osemitamab combined with nivolumab and CAPOX, revealing a median progression-free survival (PFS) of 16.6 months and an objective response rate (ORR) of 68% in 26 patients with CLDN18.2 expression ≥40%, indicating significant clinical benefits for advanced gastric cancer treatment.
  • Safety Profile Consistency: The safety data from this analysis aligns with results presented at ASCO 2025, confirming that the combination of osemitamab with standard-of-care therapy is safe and well-tolerated, thereby enhancing its potential as a first-line treatment option.
  • Impact of PD-L1 Expression: The study found that patients with higher CLDN18.2 expression exhibited better PFS outcomes across both PD-L1 CPS<1 and ≥1 subgroups, suggesting that the treatment benefit of osemitamab is consistent regardless of PD-L1 expression levels, potentially offering broader treatment options for advanced gastric cancer patients.
  • Global Development Strategy: Transcenta is developing osemitamab globally as the second CLDN18.2 targeting monoclonal antibody, leveraging advanced bioprocessing technology to enhance its anti-tumor activity, showcasing the company's strong capabilities and market potential in antibody drug development.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is TRANSCENTA-B (06628) stock price today?

The current price of 06628 is 2.64 USD — it has increased 2.72 % in the last trading day.

arrow icon

What is TRANSCENTA-B (06628)'s business?

arrow icon

What is the price predicton of 06628 Stock?

Wall Street analysts forecast 06628 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06628 is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is TRANSCENTA-B (06628)'s revenue for the last quarter?

TRANSCENTA-B revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is TRANSCENTA-B (06628)'s earnings per share (EPS) for the last quarter?

TRANSCENTA-B. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for TRANSCENTA-B (06628)'s fundamentals?

The market is revising No Change the revenue expectations for 06628 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.
arrow icon

How many employees does TRANSCENTA-B (06628). have?

TRANSCENTA-B (06628) has 0 emplpoyees as of December 05 2025.

arrow icon

What is TRANSCENTA-B (06628) market cap?

Today 06628 has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free